Compare GAUZ & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAUZ | ITRM |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Israel | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 24.3M |
| IPO Year | 2019 | 2018 |
| Metric | GAUZ | ITRM |
|---|---|---|
| Price | $0.49 | $0.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.50 | $9.00 |
| AVG Volume (30 Days) | 138.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.59 | N/A |
| Revenue Next Year | $59.03 | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.14 |
| 52 Week High | $11.00 | $1.49 |
| Indicator | GAUZ | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 33.94 | 37.15 |
| Support Level | $0.48 | N/A |
| Resistance Level | $1.59 | $0.39 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 5.16 | 24.35 |
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.